Pharmaceuticals

Oral Antidiabetic Drugs Market Forecast 2026: Where the Industry Is Headed

February 17, 2026February 17, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the oral antidiabetic drugs market from 2026–2035 with trusted insights from The Business Research Company

What upper market value could the Oral Antidiabetic Drugs Market reach by 2030 starting from 2026 levels?

The market size for oral antidiabetic drugs has shown substantial growth in recent years. It is projected to increase from $66.73 billion in 2025 to $71.42 billion in 2026, at a compound annual growth rate (CAGR) of 7.0%. The historical growth can be attributed to several factors including the limited availability of oral antidiabetic drug classes, a reliance on conventional biguanides and sulfonylureas, the increasing incidence of type 2 diabetes, expanding hospital and pharmacy distribution networks, and a rising awareness of diabetes management.

The market for oral antidiabetic drugs is projected to experience substantial expansion in the coming years. This market is predicted to reach a valuation of $92.64 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.7%. The anticipated growth during this period stems from factors such as the creation of new DPP-4 and SGLT2 inhibitors, an increase in combination treatment options, the growing acceptance of individualized medicine strategies, the expansion of online pharmacy and telemedicine platforms, and heightened governmental efforts for diabetes management. Key trends anticipated during the forecast timeframe encompass the increasing incidence of type 2 diabetes, a greater uptake of combination oral antidiabetic medications, the broadening reach of online and physical pharmacy outlets, a heightened emphasis on individualized diabetes care, and improved awareness and educational initiatives concerning diabetes.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25854&type=smp

Which Drivers Are Influencing Long-Term Growth In The Oral Antidiabetic Drugs Market?

The escalating incidence of type 2 diabetes is anticipated to stimulate the expansion of the oral antidiabetic drugs market moving forward. Type 2 diabetes is characterized as a chronic ailment where the body either exhibits insulin resistance or fails to produce sufficient insulin to sustain normal glucose levels. The rise in type 2 diabetes can be attributed to increasing obesity rates, as excess body fat contributes to insulin resistance and compromised glucose regulation. Oral antidiabetic drugs play a role in managing type 2 diabetes by enhancing insulin sensitivity, boosting insulin secretion, or reducing glucose production and absorption, thereby maintaining optimal blood sugar levels. For example, in March 2025, the Office for Health Improvement and Disparities, a UK-based government agency, reported that the prevalence of type 2 diabetes in adults aged 17+ in England increased to 7.0%, a rise from 6.8% in March 2023. Thus, the growing prevalence of type 2 diabetes is propelling the growth of the oral antidiabetic drugs market.

Which Segments Are Driving Activity In The Oral Antidiabetic Drugs Market?

The oral antidiabetic drugs market covered in this report is segmented –

1) By Drug Class: Biguanides, Dipeptidyl Peptidase-4 Inhibitors, Sodium Glucose Transport Protein -2 Inhibitors, Sulfonylureas, Thiazolidinediones, Megalitinides, Alpha Glucosidase Inhibitors, Other Drug Classes

2) By Route Of Administration: Oral, Sublingual, Buccal

3) By Therapeutic Area: Type 2 Diabetes, Gestational Diabetes, Type 1 Diabetes

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Channels

5) By End User: Hospitals, Pharmact Store, Drug Store, Diabetes Treatment Centers, Other End Users

Subsegments:

1) By Biguanides: Metformin Hydrochloride, Metformin Extended Release, Combination Products

2) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin

3) By Sodium Glucose Transport Protein-2 (SGLT2) Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin

4) By Sulfonylureas: Glipizide, Glyburide, Glimepiride, Chlorpropamide, Tolbutamide

5) By Thiazolidinediones: Pioglitazone, Rosiglitazone

6) By Meglitinides: Repaglinide, Nateglinide

7) By Alpha Glucosidase Inhibitors: Acarbose, Miglitol, Voglibose

8) By Other Drug Classes: Bromocriptine, Colesevelam

What Trends Are Reshaping The Dynamics Of The Oral Antidiabetic Drugs Market?

Leading companies within the oral antidiabetic drugs market are concentrating on clinical trials to create more effective and safer treatment choices, broaden their product ranges, and secure regulatory approvals for advanced therapies. These trials are structured research studies conducted on human participants to assess the safety, effectiveness, and potential side effects of new medical treatments, drugs, or interventions. For instance, in April 2025, Eli Lilly and Company, a US-based pharmaceutical company, launched Orforglipron, a once-daily oral small-molecule GLP-1 receptor agonist designed to streamline diabetes management following a successful phase 3 trial. This oral therapy intends to provide comparable efficacy and safety to injectable options while improving patient adherence. Clinical trials showed orforglipron reduced HbA1c (a marker of blood sugar control) by an average of 1.3% to 1.6% across different doses over 40 weeks.

Which Key Players Are Driving Competition In The Oral Antidiabetic Drugs Market?

Major companies operating in the oral antidiabetic drugs market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, C.H. Boehringer Sohn AG & Co. KG, Viatris Inc., Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., Sun Pharmaceutical Industries Limited, Cipla Limited

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/oral-antidiabetic-drugs-global-market-report

Which Region Is Projected To Lead The Oral Antidiabetic Drugs Market During The Forecast Period?

North America was the largest region in the oral antidiabetic drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral antidiabetic drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Oral Antidiabetic Drugs Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25854&type=smp

Browse Through More Reports Similar to the Global Oral Antidiabetic Drugs Market 2026, By The Business Research Company

Antidiabetics Market Report 2026

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Antidiabetics Market Report 2026

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Antidiabetics Market Report 2026

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795